01—Abstract
Summary
Summary of the 8-K filed August 14, 2026. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (LH) filed this Current Report on Form 8-K under Item 5.02, disclosing executive leadership changes.
Megan D. Bailey notified the Company on August 11, 2026 of her decision to resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Effective September 1, 2026, Brian J.
Caveney, M.D., currently Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer. In this expanded role he will be responsible for the Company's Early Development Research Laboratories and Central Laboratories businesses.
The filing does not disclose any financial results, compensation terms, or reasons for Ms. Bailey's departure. For investors, the key takeaway is a consolidation of the Central Laboratories and Early Development Research Laboratories businesses under a single executive, effective September 2026.
02—Key points
Key Highlights
- Megan D. Bailey resigned as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026; notice was given August 11, 2026.
- Brian J. Caveney, M.D., will take on the expanded role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, effective September 1, 2026.
- Caveney's new role covers both the Early Development Research Laboratories and Central Laboratories businesses.
- The filing is made under Item 5.02, covering departures of officers and appointments of certain officers.
- The filing contains no financial results, compensation arrangements, or stated reasons for the resignation.
03—Questions
Frequently Asked Questions
Why did Megan D. Bailey resign?
The filing states only that she notified the Company on August 11, 2026 of her decision to resign, effective September 4, 2026. It does not give a reason.
Who is taking over Central Laboratories?
Brian J. Caveney, M.D., will assume responsibility for the Central Laboratories business, along with the Early Development Research Laboratories business, in his new role effective September 1, 2026.
What is Dr. Caveney's current role?
He is currently Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer of the Company.
When do the changes take effect?
Dr. Caveney's new role takes effect September 1, 2026, and Ms. Bailey's resignation is effective September 4, 2026.
04—Continue